- Facing pharmacy trends for the remainder of the year
- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
- Study questions drug-discount programs
- Senate passes Drug Quality and Security Act
- Award-winning McKesson Patient Relationship Solutions on display at McKesson ideaShare 2013
WHITEHOUSE STATION, N.J. — Merck has started a clinical trial that it hopes will eventually enroll 1,700 patients to evaluate an experimental drug for Alzheimer's disease, the company said.
Merck announced the start of "EPOCH," a combined phase-2 and phase-3 study of the drug MK-8931, a 78-week trial in which patients will take either the drug in the 12-mg, 40-mg or 60-mg doses or placebo.
"Merck is committed to advancing the understanding and treatment of Alzheimer's disease," Merck Research Labs SVP and head of neuroscience and ophthalmology Darryle Schoepp said. "As the global health and financial burden of Alzheimer's disease grows, innovative research is critically needed, and we need to accelerate this research wherever possible."